Cargando…

Efficacy and safety of EUS-guided biliary drainage for benign biliary obstruction – A systematic review and meta-analysis

BACKGROUND AND OBJECTIVES: ERCP is the first line of treatment for benign and malignant biliary obstruction and EUS-guided biliary drainage (EUS-BD) is usually used for patients who have failed ERCP. Recently, several studies have evaluated the role of EUS-BD in the management of benign biliary obst...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamal, Faisal, Khan, Muhammad Ali, Lee-Smith, Wade, Sharma, Sachit, Acharya, Ashu, Farooq, Umer, Tarar, Zahid Ijaz, Faggen, Alec E., Aziz, Muhammad, Chandan, Saurabh, Ahmed, Zohaib, Kouanda, Abdul, Dai, Sun-Chuan, Munroe, Craig A., Adler, Douglas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237615/
https://www.ncbi.nlm.nih.gov/pubmed/36751758
http://dx.doi.org/10.4103/EUS-D-22-00077
Descripción
Sumario:BACKGROUND AND OBJECTIVES: ERCP is the first line of treatment for benign and malignant biliary obstruction and EUS-guided biliary drainage (EUS-BD) is usually used for patients who have failed ERCP. Recently, several studies have evaluated the role of EUS-BD in the management of benign biliary obstruction. This meta-analysis evaluates the efficacy and safety of EUS-BD in the management of benign biliary obstruction. METHODS: We reviewed several databases from inception to July 8, 2022, to identify studies evaluating the efficacy and safety of EUS-BD in the management of benign biliary obstruction. Our outcomes of interest were technical success, clinical success, and adverse events. Pooled rates with 95% confidence intervals (CIs) for all outcomes were calculated using a random effects model. Subgroup analyses were performed including patients with normal anatomy versus surgically altered anatomy (SAA). Heterogeneity was assessed by I(2) statistic. RESULTS: We included 14 studies with 329 patients. The pooled rate (95% CI) of technical success was 88% (83%, 92%). The pooled rate (95% CI) of technical success for patients with SAA and normal anatomy was 92% (85%, 96%) and 83% (75%, 89%), respectively. The pooled rates (95% CI) of clinical success and adverse events were 89% (83%, 93%) and 19% (13%, 26%), respectively. We found low heterogeneity in most of the analyses. CONCLUSIONS: EUS-BD is an effective and safe option in patients with benign biliary obstruction and should be considered after a failed attempt at ERCP or when ERCP is not technically possible.